U.S. Army Medical Materiel Development Activity (USAMMDA) logo
U.S. Army Medical Materiel Development Activity

Warfighter Expeditionary Medicine and Treatment

The Warfighter Expeditionary Medicine and Treatment Project Management Office was formed in July 2018 as the Combat Trauma and Acute Rehabilitation PMO, with the end goal of fielding U.S. Food and Drug Administration-cleared or approved medical devices, drugs, and biologics that fulfill the unmet requirements identified by the Service end user. This is accomplished either through the development of a new capability or by improving upon existing capabilities.

Our team of experts includes the Department of Defense acquisition and project management professionals, clinicians, engineers, scientists, and entrepreneurs who work together to search for innovative diagnostic and therapeutic solutions to address unique, and sometimes catastrophic injuries sustained by our Warfighters. The team provides coaching and mentorship to new companies or investigators in order to mitigate risks during development, to optimize regulatory and business strategies, and get the product to the clinic, and our Warfighters, as quickly as possible. This is accomplished by cultivating relationships with military, academia, industry and by leveraging Service laboratories to ensure that wounded Service Members have the right medical solutions in the right places in the field, and ultimately through all roles of care. The Warfighter Expeditionary Medicine and Treatment PMO addresses challenges to medical product innovation through two lines of effort: (1) Product Development and (2) Biomanufacturing Innovation.

Our focus areas include hemorrhage detection and control, improving organ support, advancing soft and hard tissue treatment and repair, managing sensory organ damage, and the enabling technologies needed to support these advancements.

  • Hemorrhage Detection and Control: This focus area aims to develop solutions to both detect internal hemorrhage and control hemorrhage in situations where normal methods of controlling hemorrhage are not effective. These solutions are needed at all roles of care, from point of injury back to the field hospital. The goal is to develop tools that will increase the survivability of the leading cause of death for Service Members in combat.
  • Organ Support: This focus area aims to develop strategies to improve the outcomes of critically injured Warfighters. In a prolonged field care setting, multiple organ injury will be expected as a complication. Products focused on supporting the organs in a field environment, with the ability to move with the Service Member as they return to a role of care 4, will be an essential component in addressing and preventing the onset of complications.
  • Soft and Hard Tissue Treatment and Repair: This focus area aims to develop a 'toolkit' of products, to include regenerative medicine solutions, for the trauma and reconstructive surgeon to restore function to wounded Warfighters. Novel products will improve limb salvage rates, decreasing the need for amputation following severe trauma; as well as provide those who have sustained severe burn injuries with the opportunity to recover faster from their injuries with improved function and appearance.
  • Sensory Organ Damage: This focus area aims to develop FDA-approved pharmacological preventives, treatments, and/or restorative interventions for sensory organ damage, whether due to traumatic injury or exposure by Active Duty Service Members. Despite wearing protective products, such as goggles for eyes and earplugs for ears, Service Members are vulnerable to ocular injuries and noise-induced hear loss while on active duty.
  • Biomanufacturing Innovation Institute: The BioFabUSA effort, funded by Office of the Secretary of Defense (OSD) Manufacturing and Industrial Base Policy as a part of the ManufacturingUSA network, aims to develop and make practical large-scale manufacturing of engineered tissues and tissue-related technologies to benefit existing industries and grow new ones. To carry out its mission, BioFabUSA will integrate innovative cell and tissue cultures with advances in biofabrication, automation, robotics, and analytical technologies to create disruptive research and development tools and FDA-compliant volume manufacturing processes. For more information please visit: https://www.armiusa.org

Last Modified Date: 12/16/2019